PURPOSE: To conduct a psychometric evaluation of the MENQOL, a condition-specific, self-report instrument to assess menopausal symptoms in women with gynecologic and breast cancers. METHODS: Identify face and content validity of the MENQOL with experts, and reliability and construct validity with a group of women diagnosed with cancer who are suffering from treatment-induced menopause. RESULTS: Eighty-two women with treatment-induced menopause completed the MENQOL, EORTC-C30, and the SVQ. The MENQOL was shown to have good face and content validity, and acceptable reliability (homogeneity and test-retest) and validity (concurrent and construct). Additionally, 85.5% of the women reported experiencing hot flashes. However, the most bothersome symptoms were weight gain and fatigue (feeling worn out). IMPLICATIONS: The MENQOL can be used to assess treatment-induced menopausal symptoms in women diagnosed with breast or gynecologic cancer.
PURPOSE: To conduct a psychometric evaluation of the MENQOL, a condition-specific, self-report instrument to assess menopausal symptoms in women with gynecologic and breast cancers. METHODS: Identify face and content validity of the MENQOL with experts, and reliability and construct validity with a group of women diagnosed with cancer who are suffering from treatment-induced menopause. RESULTS: Eighty-two women with treatment-induced menopause completed the MENQOL, EORTC-C30, and the SVQ. The MENQOL was shown to have good face and content validity, and acceptable reliability (homogeneity and test-retest) and validity (concurrent and construct). Additionally, 85.5% of the women reported experiencing hot flashes. However, the most bothersome symptoms were weight gain and fatigue (feeling worn out). IMPLICATIONS: The MENQOL can be used to assess treatment-induced menopausal symptoms in women diagnosed with breast or gynecologic cancer.
Authors: J R Hilditch; J Lewis; A Peter; B van Maris; A Ross; E Franssen; G H Guyatt; P G Norton; E Dunn Journal: Maturitas Date: 1996-07 Impact factor: 4.342
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506